$MLAB

Archbold Brian David sold $117K of MLAB

Archbold Brian David (SVP Operations) sold 1,151 shares of MESA LABORATORIES INC /CO/ (MLAB) at $101.27 ($0.12M total) on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Archbold Brian David
Published Jun 17, 2026, 4:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 4:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MLAB
Neutral
high confidence
Mentioned
$MLAB
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLABNeutralLow
01

Why it matters

The disclosure adds incremental information about insider activity but does not introduce new company fundamentals (no earnings, guidance, contracts, litigation, or regulatory actions).

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The article provides only one sale lot size and price; without context on total insider activity, buy/sell balance, or subsequent purchases, signal quality is limited.

Relevance 3/10Novelty 4/10Timing: Filed 2026-06-17; sale executed 2026-06-16

Background

This is an SEC Form 4 insider transaction disclosure for Mesa Laboratories (MLAB), reporting an officer’s open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$MLABNeutralHigh confidence
Context

MLAB disclosed an insider open-market sale by SVP Operations Archbold Brian David: 1,151 shares sold at $101.2670 on 2026-06-16 under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a routine Form 4 transaction with a stated 10b5-1 plan; no new operating, financial, or regulatory facts about MLAB are provided.

Market effects

No sector read-through; this is a single-company insider transaction with no accompanying business update.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with management’s view of valuation or liquidity needs; traders may still fade strength if selling accelerates.

Key entities

  • MLAB

    Issuer of the securities involved in the insider Form 4 transaction.

  • Archbold Brian David

    SVP Operations who sold 1,151 shares in an open-market transaction under a 10b5-1 plan.

Related articles

$MLABHighAI 9/10

Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results

Mesa Laboratories (NASDAQ:MLAB) reported 4Q26 revenues up 2.6% to $63.7M and FY26 revenues up 3.4% to $249.1M. Operating income rose 87% to $2.75M in 4Q26 and 13.3% to $18.5M in FY26. Non-GAAP AOI excluding unusual items increased 49.2% (4Q26) and 11.9% (FY26); FY26 free cash flow was $39.6M, used mainly to repay $14.7M debt, reducing net leverage to 2.11.